SARS-CoV-2 infection-related deregulation of blood lipids in a patient with -/-LDLR familial homozygous hypercholesterolemia: A case report.
J Clin Lipidol
; 17(2): 219-224, 2023.
Article
in English
| MEDLINE | ID: covidwho-2227889
ABSTRACT
BACKGROUND:
The effect of SARS-CoV-2 infection in blood lipids of homozygous familial hypercholesterolemia (HoFH) has not been explored. CASESUMMARY:
We report a case of a 43-year-old male patient with -/-LDLR HoFH with previous history of premature coronary artery disease, coronary artery bypass graft (CABG) and surgical repair of aortic valve stenosis. He presented with an abrupt decrease of his blood lipid levels during acute infection with SARS-CoV2 and subsequently a rebound increase above pre-infection levels, refractory to treatment including LDL-apheresis, statin, ezetimibe and lomitapide up-titration to maximum tolerated doses. Markers of liver stiffness were closely monitored, increased at 9 months and decreased at 18 months after the infection. Potential interactions of hypolipidemic treatment with the viral replication process during the acute phase, as well as therapeutic dilemmas occurring in the post infection period are discussed.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Homozygous Familial Hypercholesterolemia
/
Hypercholesterolemia
/
Hyperlipoproteinemia Type II
/
Anticholesteremic Agents
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
J Clin Lipidol
Journal subject:
Biochemistry
/
Metabolism
Year:
2023
Document Type:
Article
Affiliation country:
J.jacl.2023.02.001
Similar
MEDLINE
...
LILACS
LIS